S Breit1, G Hasler2. 1. Universitätsklinik für Psychiatrie und Psychotherapie Universität Bern, Bolligenstr. 111, 3000, Bern, Schweiz. 2. Universitätsklinik für Psychiatrie und Psychotherapie Universität Bern, Bolligenstr. 111, 3000, Bern, Schweiz. g.hasler@bluewin.ch.
Abstract
BACKGROUND: The objective of this article is to give an overview of the advantages and disadvantages of the use of depot antipsychotics in the treatment of schizophrenia. The focus is on efficacy, tolerability, relapse prevention, patient compliance and satisfaction compared to oral administration forms. MATERIAL AND METHODS: A literature search was conducted in medical databases. The results of meta-analyses, randomized controlled trials and systematic reviews from the years 1999-2014 were included. RESULTS AND DISCUSSION: Depot antipsychotics ensure maintenance of constant blood levels and a continuous medication delivery. The efficacy and tolerability of depot antipsychotics are comparable to oral administration forms. Due to an improved medication compliance a reduction of relapse and hospitalization rates can be achieved. This is a key focus for improving outcomes and reducing costs in the treatment of schizophrenia.
BACKGROUND: The objective of this article is to give an overview of the advantages and disadvantages of the use of depot antipsychotics in the treatment of schizophrenia. The focus is on efficacy, tolerability, relapse prevention, patient compliance and satisfaction compared to oral administration forms. MATERIAL AND METHODS: A literature search was conducted in medical databases. The results of meta-analyses, randomized controlled trials and systematic reviews from the years 1999-2014 were included. RESULTS AND DISCUSSION: Depot antipsychotics ensure maintenance of constant blood levels and a continuous medication delivery. The efficacy and tolerability of depot antipsychotics are comparable to oral administration forms. Due to an improved medication compliance a reduction of relapse and hospitalization rates can be achieved. This is a key focus for improving outcomes and reducing costs in the treatment of schizophrenia.
Entities:
Keywords:
Compliance; Health costs; Relapse; Schizophrenia; Tolerability
Authors: W Wolfgang Fleischhacker; Raymond Sanchez; Brian Johnson; Na Jin; Robert A Forbes; Robert McQuade; Ross A Baker; William Carson; John M Kane Journal: Int Clin Psychopharmacol Date: 2013-07 Impact factor: 1.659
Authors: Lizheng Shi; Haya Ascher-Svanum; Baojin Zhu; Douglas Faries; William Montgomery; Stephen R Marder Journal: Psychiatr Serv Date: 2007-04 Impact factor: 3.084
Authors: Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; David Salkever; Eric P Slade; Xiaomei Peng; Robert R Conley Journal: BMC Psychiatry Date: 2010-01-07 Impact factor: 3.630